Evidence map›Paper›PMID 28544993›Full record

ArticleDrug and alcohol dependence2017

Muscarinic receptor M

Camilla Dall, Pia Weikop, Ditte Dencker, Anna C Molander, Gitta Wörtwein, P Jeffrey Conn, Anders Fink-Jensen, Morgane Thomsen

Abstract read
In one paragraph

Article in Drug and alcohol dependence, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. [Pharmacological reports : PR · 2025
    Article
  2. Review
  3. Article
  4. Review
  5. A sex-specific effect of MFrontiers in molecular neuroscience · 2024
    Article
  6. Article
  7. Review
  8. Variability in the Drug Response of MFrontiers in pharmacology · 2019
    Article
  9. Effects of muscarinic MPsychopharmacology · 2018
    Article
  10. Autoradiography ofFrontiers in pharmacology · 2018
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Camilla DallLaboratory of Neuropsychiatry, Psychiatric Centre Copenhagen and University of Copenhagen, Copenhagen, Denmark.
Pia WeikopLaboratory of Neuropsychiatry, Psychiatric Centre Copenhagen and University of Copenhagen, Copenhagen, Denmark.
Ditte DenckerLaboratory of Neuropsychiatry, Psychiatric Centre Copenhagen and University of Copenhagen, Copenhagen, Denmark.
Anna C MolanderLaboratory of Neuropsychiatry, Psychiatric Centre Copenhagen and University of Copenhagen, Copenhagen, Denmark.
Gitta WörtweinLaboratory of Neuropsychiatry, Psychiatric Centre Copenhagen and University of Copenhagen, Copenhagen, Denmark.
P Jeffrey ConnVanderbilt Program in Drug Discovery, Vanderbilt Specialized Chemistry Center (Molecular Libraries Probe Production Centers Network; MLPCN), Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA.
Anders Fink-JensenLaboratory of Neuropsychiatry, Psychiatric Centre Copenhagen and University of Copenhagen, Copenhagen, Denmark.
Morgane ThomsenLaboratory of Neuropsychiatry, Psychiatric Centre Copenhagen and University of Copenhagen, Copenhagen, Denmark; Alcohol and Drug Abuse Research Center, McLean Hospital/Harvard Medical School, Belmont, MA, USA. Electronic address: mthomsen@mclean.harvard.edu.
University of Copenhagen · DKVanderbilt University Medical Center · US

Funding

The Vanderbilt Specialized Chemistry Center for Accelerated Probe DevelopmentU54MH084659 · NIMH · VANDERBILT UNIVERSITY · PI LINDSLEY, CRAIG · 2008 to 2013
$24.1M
Research Project: Sensory and Multisensory Contributions to AutismU54HD083211 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WALLACE, MARK THOMAS · 2015 to 2019
$7.1M
Selective Muscarinic Receptor Ligands as Targets for Cocaine Addiction MedicationR00DA027825 · NIDA · MCLEAN HOSPITAL · PI THOMSEN, MORGANE HERMANN · 2012 to 2014
$710k
Selective Muscarinic Receptor Ligands as Targets for Cocaine Addiction MedicationK99DA027825 · NIDA · MCLEAN HOSPITAL · PI THOMSEN, MORGANE HERMANN · 2010 to 2011
$247k
NICHD NIH HHS U54 HD083211NIDA NIH HHS K99 DA027825NIDA NIH HHS R00 DA027825NIMH NIH HHS U54 MH084659
6 · The paper itself

Abstract

backgroundCocaine addiction is a chronic brain disease affecting neurotransmission. Muscarinic cholinergic receptors modulate dopaminergic signaling in the reward system, and muscarinic receptor stimulation can block direct reinforcing effects of cocaine. Here, we tested the hypothesis that specific muscarinic M

methodsWe tested the M

resultsVU0152100 attenuated the discriminative stimulus effect of cocaine in wild-type mice and M

conclusionsThese findings further support the notion that M

Indexed as

CocaineAnimalsCocaine-Related DisordersCorpus StriatumHyperkinesisMaleMiceMice, KnockoutPyridazinesPyridinesReinforcement, PsychologyRewardThiophenes3-amino-N-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide5-amino-3,4-dimethyl-N-(4-((trifluoromethyl)sulfonyl)benzyl)thieno(2,3-c)pyridazine-6-carboxamideCocainePyridazinesPyridinesThiophenesAbuseAddictionClassical conditioningDiscriminative stimulusMuscarinic cholinergicPsychostimulant

Identifiers

PMID28544993
PMCPMC6423356
OpenAlexW2616085155

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.